US Federal 2025-2026 Regular Session

US Federal House Bill HB1690

Introduced
 
Introduced
2/27/25  

Caption

SCREEN Act

Summary

HB1690, the SCREEN Act, would restrict the Department of State from providing technical support or access to federal assets for film production or financing unless a U.S. company discloses certain dealings with the Chinese government or Chinese Communist Party (CCP). To qualify, a company would have to identify films whose content was submitted to PRC or CCP officials for review over the prior 10 years, provide the film titles and submission dates, and sign an agreement not to alter film content in response to, or in anticipation of, Chinese government or CCP requests. The bill also bars federal support or contracts for films co-produced with PRC entities subject to Chinese content conditions, and for companies identified in the required State Department reports as having altered film content for Chinese approval. The Secretary of State would have to report to Congress within 180 days and annually thereafter on disclosed films, agreements, and any films the Department assesses were altered for Chinese censorship or market access.

Impact

The bill would add a new federal restriction on the use of Department of State-controlled assets and technical support in connection with film production and financing. It would also create a recurring reporting requirement to the House Foreign Affairs Committee and Senate Foreign Relations Committee, and it would effectively condition certain federal film-related assistance on transparency about interactions with PRC or CCP officials and on commitments not to censor content for the Chinese market. The measure would primarily affect U.S. film companies that seek federal support or access tied to State Department assets, especially those with business relationships in China.

Sentiment

The available context shows no recorded committee debate or votes, so there is no documented floor or committee sentiment to measure. Based on the bill text and its framing, the measure appears to be driven by concern over Chinese Communist Party influence and censorship in the film industry, suggesting support from sponsors focused on anti-CCP policy and skepticism toward U.S. companies that alter content for access to the Chinese market. No opposing arguments are captured in the provided materials.

Contention

The central point of contention is likely whether the federal government should condition support for film production on disclosures about, and resistance to, Chinese censorship demands. Supporters would likely argue the bill protects free expression and prevents U.S. companies from accommodating CCP influence, while critics may view it as burdensome, difficult to administer, or overly broad in reaching private film business decisions and international co-productions. Another likely issue is the bill’s reliance on the Secretary of State’s assessment that content was altered in response to Chinese requests, which could raise evidentiary and enforcement concerns.

Companion Bills

No companion bills found.

Previously Filed As

US SB189

Relating To Breast Cancer Screening.

US SB189

Relating To Breast Cancer Screening.

US SB3741

NEWBORN SCREENING ACT CHANGES

US SB2790

IDPH-LUNG CANCER SCREENING

US HB3726

IDPH-LUNG CANCER SCREENING

US S1578

Coverage for Mammograms and Supplemental Breast Cancer Screenings

US S1494

Insurance Coverage for Breast Cancer Screening

US SB448

Relating to brain injury screening training

US S0524

Newborn Screenings

US HB4215

NEWBORN HEARING SCREENING

Similar Bills

No similar bills found.